Traded Nov 9, 2026 · largest single transaction ~$380KNot reported under a pre-arranged trading plan
Show all 2 transactions
Nov 9, 2026~$380K · 4,000 sh @ $94.98
DetailsOfficial recordNov 9, 2026~$5.5K · 59 sh @ $93.96
DetailsOfficial record
Ask OQRO reads the filings behind this page and answers in plain words, with a link to each source.
Ask OQRO is part of OQRO Pro. Everything else on OQRO is free.
Only to see which pages are hard to use, so we can fix them. Nothing is used for ads, and what you type stays hidden (Microsoft Clarity, PostHog). Privacy Policy
TMDX · NASDAQ · Health Care Equipment
TransMedics Group, Inc. (TMDX) · oqro.io/stocks/TMDX · printed today. Every figure comes from a public filing, linked on the page online. Not investment advice.
$85.25−8.77 (−9.33%)
Close of Nov 20, 2026, vs Nov 19 · end-of-day
2 routine filings (option exercises, shares withheld for taxes, grants, gifts) are not listed here. Show them
Traded Nov 9, 2026 · largest single transaction ~$380KNot reported under a pre-arranged trading plan
Nov 9, 2026~$380K · 4,000 sh @ $94.98
DetailsOfficial recordNov 9, 2026~$5.5K · 59 sh @ $93.96
DetailsOfficial recordJames R. Tobin (Director) plans to sell ~$385K of TransMedics Group, Inc.
Planned, from payTraded Aug 6 – Aug 7, 2025 · largest single transaction ~$997K
Aug 6, 2025~$997K · 8,400 sh @ $118.68
DetailsOfficial recordEdward M Basile (Director) sold ~$520K of TransMedics Group, Inc.
Planned saleAnil P. Ranganath (See remarks) sold ~$96K of TransMedics Group, Inc.
Automatic saleEdward M Basile (Director) sold ~$632K of TransMedics Group, Inc.
Planned saleInsider selling
Traded May 23, 2025 · filed the same dayNot reported under a pre-arranged trading plan
A TransMedics director sold $91K of TransMedics shares. The filing does not indicate a pre-arranged trading plan.
Edward M Basile (Director) sold ~$694K of TransMedics Group, Inc.
Planned saleTamer I Khayal (Chief Commercial Officer) sold ~$184K of TransMedics Group, Inc.
Automatic saleTamer I Khayal (Chief Commercial Officer) sold ~$87K of TransMedics Group, Inc.
Planned saleTamer I Khayal (Chief Commercial Officer) sold ~$94K of TransMedics Group, Inc.
Planned saleTamer I Khayal (Chief Commercial Officer) sold ~$131K of TransMedics Group, Inc.
Planned saleEdward M Basile (Director) sold ~$441K of TransMedics Group, Inc.
Planned saleEdward M Basile (Director) sold ~$123K of TransMedics Group, Inc.
Planned saleTamer I Khayal (Chief Commercial Officer) sold ~$89K of TransMedics Group, Inc.
Planned saleWaleed H Hassanein (President & CEO) sold ~$476K of TransMedics Group, Inc.
Planned saleWaleed H Hassanein (President & CEO) sold ~$467K of TransMedics Group, Inc.
Planned saleWaleed H Hassanein (President & CEO) sold ~$161K of TransMedics Group, Inc.
Planned saleWaleed H Hassanein (President & CEO) sold ~$41K of TransMedics Group, Inc.
Planned saleTamer I Khayal (Chief Commercial Officer) sold ~$132K of TransMedics Group, Inc.
Planned saleTamer I Khayal (Chief Commercial Officer) sold ~$120K of TransMedics Group, Inc.
Planned saleTamer I Khayal (Chief Commercial Officer) sold ~$78K of TransMedics Group, Inc.
Planned saleTamer I Khayal (Chief Commercial Officer) sold ~$48K of TransMedics Group, Inc.
Planned saleTamer I Khayal (Chief Commercial Officer) sold ~$21K of TransMedics Group, Inc.
Planned saleTamer I Khayal (Chief Commercial Officer) sold ~$12K of TransMedics Group, Inc.
Planned saleTamer I Khayal (Chief Commercial Officer) sold ~$12K of TransMedics Group, Inc.
Planned saleTamer I Khayal (Chief Commercial Officer) sold ~$12K of TransMedics Group, Inc.
Planned saleTamer I Khayal (Chief Commercial Officer) sold ~$3.1K of TransMedics Group, Inc.
Planned saleAug 7, 2025~$768K · 6,617 sh @ $116.08
DetailsOfficial recordAug 7, 2025~$217K · 1,858 sh @ $116.85
DetailsOfficial record0 open-market purchases and 2 open-market sales by insiders of TMDX between Jan 25, 2026 and today, placed against the company's last 4 earnings releases. The latest on file was filed Nov 5, 2026. The data provider lists the next release for Feb 22, 2027; that date may change.
PurchaseSale30 days before a release30 days after
| Earnings release | 30 days before | On the day | 30 days after |
|---|---|---|---|
| Nov 5, 2026 | None | None | 2 sales |
| Aug 4, 2026 | None | None | None |
| May 5, 2026 | None | None | None |
| Feb 24, 2026 | None | None | None |
Companies set trading windows, which usually close shortly before results and reopen after them, and insiders may trade under 10b5-1 plans adopted months earlier. A date alone does not show what a person knew or why they traded. Past release dates are the dates the company filed its 8-K with Item 2.02. An upcoming date, when one is mentioned, comes from the data provider's earnings calendar (Finnhub): it is not a company filing, it is not estimated by OQRO, and it may change. Open-market purchases and sales as reported on Form 4. Largest purchases around earnings, all companies